** Healthcare services co Healius HLS.AX announces high single-digit EBIT margin target for FY27, exceeding estimates of Citi and Jefferies
** Market might maintain healthy level of scepticism about this target given previous false starts and valuation that is still relatively high, Citi says
** Jefferies notes potential for significant EBIT uplift, but says it will update its forecasts in line with delivery of these targets
** Jefferies also sees green shoots in Australian healthcare services and hopes HLS can benefit from this
** Citi maintains its target price at A$1.05 and rating at "neutral"; Jefferies raises target price from A$1.45 to A$1.65, keep "hold" rating
** Stock up 5.8% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。